The meeting was opened by David Innes as chairman of the CLLSA. This was followed by a presentation by Dr Follows talking about CLL - The disease and its treatment in 2017 and beyond. The afternoon session started with facilitated small group discussions. An opportunity to share tips for coping with CLL and was then followed by three stories from individuals affected by CLL.
Liverpool Members conference May 2017 - videos available here
There were four presentations videoed at this meeting,
PRESS RELEASE
AbbVie launches first ever series of mindfulness podcasts to support people living with blood cancers
In collaboration with AbbVie, mindfulness expert Dr Caroline Hoffman has developed a series of new podcast audio recordings specifically tailored to help support people living with blood cancers, and their partners or carers
The National Institute for Health and Care Excellence (NICE) has issued a second Appraisal Consultation Document (ACD) not recommending the routine National Health Service use of Venclexta (venetoclax) for patients with certain types of difficult-to-treat relapsed and refractory chronic lymphocytic leukemia (CLL).
There were 4 medical presentations: two given by
Dr Alison McCraig Affiliate (Paul O'Gorman Leukaemia Research Centre) Glasgow University
as well as presentations by
Dr Emilio Cosimo Research Associate (Paul O'Gorman Leukaemia Research Centre) Glasgow University
Dr Ailsa Holroyd Clinical Research Fellow (Institute of Cancer Sciences) Glasgow University.
The presentations can be found here.
European Medical Agency - On 21 April 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rixathon, intended for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).
Dr Claire Dearden gave two very interesting talks at the London meeting. Understanding CLL - Who and when to treat and How to treat in 2016 and beyond
Rupert Beazley a patient and trustee offers his experience of CLL and treatment. They can be found here.
Four very helpful talks by the Southampton team were recorded at the CLLSA members Conference last summer. We hope you find them of interest
CLLSA are extremely pleased by the NICE decision to approve Ibrutinib to treat NHS England and Wales chronic lymphocytic leukaemia patients.
Today’s Final Appraisal Determination (FAD) recommends that:
1.1Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:
· who have had at least 1 prior therapy or
CLLSA is pleased to share that the Accelerated Access Review final report has now been published; it has been long awaited.
Telephone Support Helpline